Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
updated 5/15/2020 Ayvakit - Approved January 9th, 2020 On January 9, 2020, The FDA approved avapritinib, brand name Ayvakit (formerly BLU-285), for GISTs with a mutation in exon 18 of the platelet derived [...]
Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
CTOS, "The Connective Tissue Oncology Society", is an organization of medical specialists and researchers who specialize in bone and soft tissue tumors. They hold a meeting every year to discuss the latest innovations in this area. This year the meeting took place in Tokyo from November 13 until 16.
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]
International advocates meet in Wayne, NJ, at the annual New Horizons GIST Conference to discuss scientific updates, regional issues, and unmet needs for the global GIST community in May 2019.
As part of our Faces of Courage Series, we are featuring a patient story on the 13th of each month. Why is the number 13 significant? 5,000 people are diagnosed with GIST each year [...]
As part of our Faces of Courage Series, we are featuring a patient of the month on the 13th of each month. Why is the number 13 significant? 5,000 people are diagnosed with GIST each [...]
Left to right: Laura Occhiuzzi, Pete Knox, Alyssa O’Driscoll, Sarcoma Alliance, Annie Achee, National LeioMyoSarcoma Foundation, Denise Reinke, SARC, and Mitch Achee, National LeioMyoSarcoma Foundation. GIST Research from CTOS 2018 A web-based [...]